Current Evidence on GLP-1 Exposure, Pregnancy Risks and Infant Outcomes
- Pregestational diabetes affects approximately 1-2% of pregnancies worldwide.
- Pregestational diabetes poses significant medical challenges during pregnancy, heightening the likelihood of various potential complications for the pregnant individual and their unborn child.
- There has been a noticeable rise in the usage of GLP-1 receptor agonist medications among individuals with type 2 diabetes in recent years.
- According to a recent study, using GLP-1 receptor agonists during pregnancy does not pose a higher risk of congenital malformations than insulin therapy.
- It is predicted that there will be a continued rise in the number of infants who are exposed to these drugs during pregnancy, according to scientists.
Pregestational diabetes, a condition in which diabetes is already present before pregnancy, affects approximately 1-2% of pregnancies worldwide.
Pregestational diabetes can cause an increased risk of miscarriage, stillbirth, and preterm labour. Having a low birth weight can also have long-term health consequences for the baby, increasing the risk of diabetes, obesity, and heart disease later in life.
Additionally, having this condition can heighten the chances of experiencing various complications during pregnancy, such as congenital disabilities, miscarriage, fetal growth restriction, premature labour, and preeclampsia.
The use of GLP-1 receptor agonist medications such as Ozempic and Trulicity has seen a rise in pregnant individuals with type 2 diabetes, indicating the continued importance of diabetes medication in managing their condition during pregnancy.
According to recent research, the risk of major infant congenital malformations is not increased when using second-line noninsulin antidiabetic medications like GLP-1 receptor agonists, as compared to using insulin.
This could have implications for the health of these children, as long-term exposure to antidiabetic medications can have a variety of side effects. Further research is needed to understand better the long-term effects of prenatal exposure to antidiabetic medications.
Lack Of Data On The Effects Of Glp-1 Drugs On Pregnancy
Pregestational diabetes is a frequently encountered medical complication during pregnancy.
GLP-1 receptor agonists have become widely accepted as effective and well-tolerated alternatives to subcutaneous insulin injections for treating type 2 diabetes, thanks to their efficacy and tolerability.
While these agents have the potential to improve patient acceptability and adherence, leading to better glycemic control and pregnancy outcomes, their safety during pregnancy remains unknown, mainly due to the exclusion of pregnant women from clinical trials. As a result, treatment guidelines currently do not recommend the use of these agents in pregnancy.
As a result, pregnant women have been hesitant to use second-line noninsulin antidiabetic medications due to the limited information available regarding their safety during pregnancy. This lack of data has hindered the potential benefits of these medications for individuals who cannot or prefer not to use insulin injections.
Hence, it was imperative to conduct research and gather data on the safety of these medications to address the growing number of unplanned pregnancies occurring while individuals are undergoing treatment with these drugs.
Ccc 3.5 million pregnancies analysed from 2009 to 2021, approximately 52,000 involved individuals with pregestational type 2 diabetes. Within the three months preceding or following pregnancy, around 15,000 of these individuals were prescribed a noninsulin antidiabetic medication as a first- or second-line treatment.
The study revealed a significant increase in the occurrence of major congenital malformations, particularly cardiac malformations, among infants born to individuals with pregestational type 2 diabetes compared to the general population.
In contrast, the study found that the risk of major congenital malformations was not significantly different between infants born to people with type 2 diabetes who took a second-line noninsulin antidiabetic medication, such as GLP-1 receptor agonists and infants exposed to insulin.
Although the study provides some reassurance that the new diabetes drugs do not have a significant risk of congenital disabilities in early pregnancy, there is still limited data due to the low number of women who used these drugs. Therefore, additional research must validate these findings and provide more accurate estimates.
Prenatal Exposure To GLP-1 Drugs Increases.
The researchers also noted a rising trend in utilising second-line noninsulin antidiabetic medications, particularly GLP-1 receptor agonists. This suggests that the population of infants exposed to these drugs during pregnancy is expected to grow even further.
Throughout the study period, there was a noticeable increase in diabetes prevalence among women in the reproductive age group. Furthermore, there was a significant uptick in utilising newer antidiabetic drugs, particularly GLP-1 receptor agonists. Because not all pregnancies are intentional, an increasing number of individuals were conceiving while undergoing treatment with these medications.
As the use of GLP-1 receptor agonists like semaglutideTrusted Source — Wegovy, Ozempic — expands, the prevalence of infants exposed to these medications during pregnancy is expected to rise steadily.
As a result, more and more patients and healthcare professionals will seek information regarding the safety of GLP-1 receptor agonists in the early stages of pregnancy. Our research is of great importance as it offers preliminary evidence that these medications are safe for infants exposed to them during pregnancy.
Providing Improvement For Infant Health
Second-line noninsulin antidiabetic medications like GLP-1 receptor agonists have shown to be safe for use during pregnancy, as they share similarities with previously used medications like metformin and glyburideTrusted Source in treating pregestational diabetes.
For women with type 2 diabetes who are planning to get pregnant, it is crucial to maintain a haemoglobin A1C level below seven. This can be achieved by using GLP-1 medications, which effectively control blood sugar levels. It is important to note that having a haemoglobin A1C level above seven can increase the risk of anomalies, particularly those related to heart health, by 15%.
When evaluating the risks and advantages of using medications during pregnancy, it is essential to prioritise the well-being of both the mother and the fetus. The available information suggests that these medications can improve glycemic control and have minimal adverse effects on the fetus. However, further research is necessary to understand the long-term implications fully.
Connect with one of our doctors at Mobi Doctor with the click of a button and receive the care you require.
